Market to an a we’re strong build wide representing to business, of has markets Suite more broad of on across the end as set to of customers, of Proteograph pleased continue increasing and Thanks, a with response Carrie. Product geographies. year. potential the our be start with I our the range strong engaging number trajectory could we not been positive
and Proteograph already of to Product XXXX, we revenue the collaboration relatively we’re important geographies our customers, quarter by that from small phase commercialization set in milestone, with This year, operational of our continued on one, would commercial of Suite. data customer first expect the breadth of number they’ve phase the three-phase our the three, to-date, we’re for four, sales our even quality in broad to XXXX. into the move release a I’m high Building our we globe. in of performance where the and and we reporting into include, phase, commercial the limited customers, depth currently the and the sample encouraged early execution, through quarters These our our hands ahead from expectations the related the we approach. as thought overall the achieved release product we sizes an of two depth and Coming of used team, level pipeline, on we be enter generated interest two, across fronts.
market underway We’re select excellent with of in working release, customers limited well making across key our progress and segments. set
using and Suite, are release their getting of the the Customers of Product limited number XXXX. Proteograph Suite customer, customer first data the risk expand release with the on multiple installed excited they’re running, and by now in our Proteograph track a up at onboard We’ve and samples. performance continues single-digit Our mature. to customers own international they’re shipped prospective Product the limited we’re funnel to including which sites, speed high and generating of and
a Knight be able only is use and and Proteograph Product a of affirming to unprecedented in first with QX research, early prospective amino my from demonstrating that enabled was of and generated to across expectation customers a their Proteograph exceeded data truly Proteograph to They pilot our play with proteome is our of the proteomic that platform. role of is that to the secure customers funding initiate of deep is Suite easily would level to protein has affecting undertaken This for last depth essential wide from Product least greater in year. demonstrate of XXXX understanding proteomic can and enormous data and in to-date. We’re disruptive to and this is Suite resolution order at fall. the this by customer discovery to and acid plasma from Proteograph cancer specific the any access including and prostate being the will for power working the health access complexity breadth successfully customers study samples. an data early institute resolution. detection receive expect the be were up the and sometime Institute The applications, study than project level proteome project OHSU late Cancer range at biomarker of magnitude early XXX This They possibly Initial closely least at product the and our enable variants the at discovery. speed the unbiased generated scale disease.
aiming customers, to workflow Institute for study compare known. already which unbiased previously they In the that workflows Proteograph using Another fractionation had data to the Broad the samples the analyzed proteomics. use of depletion for extensive was patient our to Proteograph essence, they Product and Suite were
abundant time biomarkers. to With original as the of depletion fractionation area, the compared in proteins workflow. were the was detect and small fraction low study disease a Proteograph, This in significance known completed the novel of able to as well they candidate
provided which much Proteograph the previously coverage studies breadth and Importantly, possible. not and ease-of-use, enable of proteomic speed larger depth this with will reproducibility,
a global run of workflow. Proteograph Suite with compared expertise would in Product who deep CRO processed Proteograph majority number When a were of to to comparing able workflow times existing under the their samples and of results, example the samples with set biomarkers. identify detect unbiased proteomics, the deep previously samples yielded the proteomic proteins under approved compared X running unbiased be existing they FDA Another the
scale, range dynamic resolution. interest in example higher proteomic. abundance the able unprecedented disease detect protein uniquely It are Proteograph cytokines While to and low the broad that customers proteome forward very also to are access clear pathogenesis. speed acid of of these at are This abundant amino plasma is as side large they scale number such of is using to is on deep of our that the data another a unbiased with proteins for proteomics to that provides scale large unbiased were of the most the perform of that plasma eager move level studies biomarkers
despite resulted Proteograph only Product early many that our data possible already customers weeks installed of fact or the Suite upcoming what’s vision In their months submission data, conferences. have expanding fact, with abstracts of near the are as were that seeing of fall in they’re the numerous research. customers compelling for And have the ago, generated the
from from We expect customers, into head as and publications to potentially see peer-reviewed we XXXX. of including Seer this activity more
We geographies also interest significant continue and to outside see particular, especially China. U.S., the from region, from in Asia-Pacific
established Medical. for we’re announce this to the Suite. Given delighted market. continuum across is but significant our partner Product of Proteograph a institutions enable a technology of to Proteograph region only for valuable specific excited region robust the given not and our Suite opportunity Enlight partner to market Product space with in critical immediate to will accelerate to strategy significant China. the also and sites, and China as in expertise our across a of decided expertise establishing into We access a the the Enlight level in to to our this access high with the China we be customer entry Proteograph We Olink clinical China. Enlight partners that access distribution for this China Product have Suite component us we of afternoon interest the We research distributor, performance in with across believe the a regulatory as were view entire
innovations, model from protein include some an expect further months, of across will already we what to which the coverage, As innovations the volume Suite types, over we’re more and Product of organisms. up envelope expand capability disruptive sample next of the driving increasing Proteograph driving and coming customer with a set I expand is use hear increasing of pushing number about of footprint the also product, with down us these optimizing you throughput, our
committed continuous absolutely us to products team, ingenuity in our new delivering enhancements pace the of their their possible. for set that never driving will and stream proud innovation to that of commitment product allow We’re to I’m extremely access a proteome and ways before proteomics. in the products
of business. our strong all We’re progress dimensions making across
the customers, enthusiasm to future and Proteograph and our towards have ambitions will front our more of onset and that, the progress. the impact have while by call be a we the with I’m disease. the product there’s much to of now health on for enhance we’re of I we’re together the can detail of growing Omead in our at Suite, milestone to the and and our us. still turn revenue significant inspired so successes execute, first quarter We early reached for the our journey accelerating to opportunity done With with over of Product commercial understanding projects
